Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AB Science S.A. is a biopharmaceutical company focused on the development of protein kinase inhibitors for the treatment of various diseases, including oncology and neurodegenerative disorders. Its lead product, masitinib, is being evaluated in multiple clinical trials across Europe and the U.S., positioning the company uniquely within the specialty pharmaceuticals sector.
AB Science generates revenue primarily through the commercialization of its lead drug, masitinib, which targets multiple indications. The company benefits from a robust pipeline and potential partnerships with larger pharmaceutical firms, providing it with pricing power and a competitive edge in niche therapeutic areas.
Clinical trial results for masitinib, particularly in oncology and neurodegenerative diseases
Regulatory approvals in key markets such as the EU and U.S.
Partnership announcements or licensing deals with larger pharmaceutical companies
Market sentiment regarding the biotech sector and funding availability
Regulatory changes that could impact drug approval processes
Technological disruption in drug development methodologies
Emergence of new therapies that could outperform masitinib
Increased competition from generic drug manufacturers
Negative cash flow and reliance on external funding
Potential dilution from future capital raises
moderate - As a biotech firm, AB Science's performance is somewhat insulated from economic cycles, but funding for R&D can be affected by broader economic conditions.
Higher interest rates may increase the cost of capital for AB Science, impacting its ability to finance clinical trials and operations, which could pressure valuations.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has exhibited significant price volatility, reflecting the inherent risks in clinical trial outcomes and regulatory approvals.
